NAD+observational2018

Biophysical characterization of hit compounds for mechanism-based enzyme activation.

PloS one

confidence

Key findings

Introduces a general mode of sirtuin activation distinct from known modes, based on conserved deacylation mechanism; no clinical/biological endpoints reported.

View source on PubMed (PMID 29547630) ↗

Sample size
Not reported
Population
Not applicable (biophysical study of sirtuin enzyme activation)
Dosing
Not reported
Duration
Not reported
Route
Not reported
Blinding
not_reported
Controls
not_reported
Drug class
coenzyme
Full abstract

Across all families of enzymes, only a dozen or so distinct classes of non-natural small molecule activators have been characterized, with only four known modes of activation among them. All of these modes of activation rely on naturally evolved binding sites that trigger global conformational changes. Among the enzymes that are of greatest interest for small molecule activation are the seven sirtuin enzymes, nicotinamide adenine dinucleotide (NAD+)-dependent protein deacylases that play a central role in the regulation of healthspan and lifespan in organisms ranging from yeast to mammals. However, there is currently no understanding of how to design sirtuin-activating compounds beyond allosteric activators of SIRT1-catalyzed reactions that are limited to particular substrates. Here, we introduce a general mode of sirtuin activation that is distinct from the known modes of enzyme activation. Based on the conserved mechanism of sirtuin-catalyzed deacylation reactions, we establish biophysical properties of small molecule modulators that can in principle result in enzyme activation for diverse sirtuins and substrates. Building upon this framework, we propose strategies for the identification, characterization and evolution of hits for mechanism-based enzyme activating compounds.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.